Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001387131-19-002230)

Filing Details

Accession Number:: 0001387131-19-002230
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-03-28 17:13:49
Reporting Period:: 2019-03-26

Accepted Time:: 2019-03-28 17:13:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1430306	Tonix Pharmaceuticals Holding Corp.	TNXP	Pharmaceutical Preparations (2834)	261434750

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563420	Seth Lederman	C/O Tonix Pharmaceuticals Holding Corp 509 Madison Ave., Suite 1608 New York NY 10022	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Acquisiton	2019-03-26	25,000	$2.38	27,670	No	4	P	Indirect	By 401(k) plan

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By 401(k) plan

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	1,767	Direct
Common Stock, $0.001 Par Value	4,590	Indirect	By IRA Account
Common Stock, $0.001 Par Value	310	Indirect	By spouse
Common Stock, $0.001 Par Value	292	Indirect	By Leder Laboratories, Inc.
Common Stock, $0.001 Par Value	292	Indirect	By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 Par Value	2,047	Indirect	By Lederman & Co., LLC
Common Stock, $0.001 Par Value	325	Indirect	By L&L Technologies, LLC
Common Stock, $0.001 Par Value	590	Indirect	By Targent Pharmaceuticals, LLC

Footnotes

Weighted average purchase price. Actual purchase prices ranged from $2.335 to $2.40.
Reporting person may be deemed to be a control person of this entity.